What is Mesothelioma
Stages of Mesothelioma
• Clinical Trials
• Palliative Care
Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo
in Advanced Malignant Pleural Mesothelioma
Basic Trial Information
Phase: Phase III
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2005_010, NCT00128102
This is a study to determine the safety, tolerability, and anti-tumor
effectiveness of an oral investigational drug, suberoylanilide hydroxamic
acid, in the treatment of advanced malignant pleural mesothelioma.
Patient must be 18 years or older with confirmed
diagnosis of malignant pleural mesothelioma.
Patient must have failed prior chemotherapy that
included pemetrexed with either cisplatin or carboplatin.
Patient must have adequate bone marrow, liver and
Patient must be capable of self-care and out of
bed for more than 50% of waking hours.
Patient must have ability to swallow pills.
- Patient has been treated with other investigational agent that
has similar properties
- Patient has an active infection within 2 weeks of the start of
study drug, or had treatment with intravenous antibiotic, antiviral,
or antifungal medications within 2 weeks of the start of study drug.
- Patient is pregnant or breast feeding
Information about this trial is from the ClinicalTrials.gov database.
The versions designated for health professionals and patients contain
the same text. Minor changes may be made to the ClinicalTrials.gov
record to standardize the names of study sponsors, sites, and contacts.
Cancer.gov only lists sites that are recruiting patients for active
trials, whereas ClinicalTrials.gov lists all sites for all trials.
Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Trial Contact Information
Trial Lead Organizations
Merck and Company, Incorporated
Medical Monitor Study Director
Toll Free US Number Ph: 1-888-577-8839
Trial Sites and Contacts
Merck Sharp & Dohme De Espana, S.A.E.
Jorge Gonzalez-Esteban, Dr.
Ph: 34 91 3210726